Literature DB >> 48211

Cerebrospinal fluid proteins in multiple sclerosis.

G Lamoureux, R Jolicoeur, N Giard, M St-Hilaire, F Duplantis.   

Abstract

Various CSF proteins were studied in 255 definite multiple sclerosis patients at various disease stages and compared with corresponding values obtained from 174 controls. The CSF changes in acute multiple sclerosis patients included a significant increase of total proteins and of gamma globulin, IgG, IgA, IgM, alpha-2 ceruloplasmin, 7S-gamma-1, and cytotoxic index for nerve cells in tissue culture, and significant decreases of pre-albumin, alpha-1, and alpha-2 and of the beta/gamma globulin ratio. The CSF levels of IgG, IgA, and IgM remained significantly higher in steroid-treated multiple sclerosis patients than in controls, but the levels often were significantly reduced while patients were on treatment or in remission. During remission or treatment with ACTH and/or steroids, the alpha-2 ceruloplasmin, 7S-gamma-1, and cytotoxic index were significantly reduced and the pre-albumin, alpha-1, and alpha-2 globulin classes and the beta/gamma ratio showed a tendency to return to normal.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 48211     DOI: 10.1212/wnl.25.6.537

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

Review 1.  Inflammatory and autoimmune diseases of the nervous system; possibilities of laboratory diagnostic methods in cerebrospinal fluid.

Authors:  Z Lodin
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

2.  Isoelectric focusing and quantitative estimation of cerebrospinal fluid and serum IgG in idiopathic polyneuropathy.

Authors:  P Livrea; G B Zimatore; I L Simone; M Trojano; V Lepore; V Ferrara; F A Lupo; D Pedone
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

3.  Modifications of the cerebrospinal fluid IgG concentrations in patients with multiple sclerosis treated with intrathecal steroids.

Authors:  A R Massaro
Journal:  J Neurol       Date:  1978-12-22       Impact factor: 4.849

4.  A clinical and immunological study of the effects of transfer factor on multiple sclerosis patients.

Authors:  G Lamoureux; J Cosgrove; P Duquette; Y Lapierre; R Jolicoeur; F Vanderland
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

5.  Antibody to myelin basic protein in extracts of multiple sclerosis brain.

Authors:  C C Bernard; V B Randell; L B Horvath; P R Carnegie; I R Mackay
Journal:  Immunology       Date:  1981-07       Impact factor: 7.397

6.  Immunological features in multiple sclerosis.

Authors:  G Lamoureux; N Giard; R Jolicoeur; V Toughlian; M Desrosiers
Journal:  Br Med J       Date:  1976-01-24

7.  Cerebrospinal fluid and serum prealbumin (transthyretin) in patients with multiple sclerosis (MS): comparison of particular subgroups of MS patients.

Authors:  M Hybelová; J Svatonová; O Sobek; P Adam; D Dolezil; D Adam
Journal:  Folia Microbiol (Praha)       Date:  2009-05-06       Impact factor: 2.099

8.  Changes in Serum Ceruloplasmin Levels Based on Immunomodulatory Treatments and Melatonin Supplementation in Multiple Sclerosis Patients.

Authors:  Monika Adamczyk-Sowa; Paweł Sowa; Sebastian Mucha; Jacek Zostawa; Bogdan Mazur; Maciej Owczarek; Krystyna Pierzchała
Journal:  Med Sci Monit       Date:  2016-07-15

9.  Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen.

Authors:  Andreas Totzeck; Benjamin Stolte; Kathrin Kizina; Saskia Bolz; Melina Schlag; Andreas Thimm; Christoph Kleinschnitz; Tim Hagenacker
Journal:  Int J Mol Sci       Date:  2019-10-30       Impact factor: 5.923

10.  Alterations of peripheral nerve excitability in an experimental autoimmune encephalomyelitis mouse model for multiple sclerosis.

Authors:  Nathalia Bernardes Teixeira; Gisele Picolo; Aline Carolina Giardini; Fawzi Boumezbeur; Géraldine Pottier; Bertrand Kuhnast; Denis Servent; Evelyne Benoit
Journal:  J Neuroinflammation       Date:  2020-09-07       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.